Literature DB >> 12712416

Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding.

Michael J Banker1, Tracey H Clark, John A Williams.   

Abstract

A 96-well equilibrium dialysis block was designed and constructed that is compatible with most standard 96-well format laboratory supplies and instruments. The unique design of the dialysis apparatus allows one to dispense and aspirate from either or both the sample and dialysate sides from the top of the apparatus, which is not possible with systems currently on the market. This feature permits the investigator to analyze a large number of samples, time points, or replicates in the same experiment. The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-volume ratio, eliminates problems associated with trapped air pockets, and allows one to add or remove samples independently or all at once. Furthermore, the design of the apparatus allows both the sample and dialysate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated. Teflon construction is used to minimize nonspecific binding of test samples to the apparatus. The device is reusable, easily assembled, and can be shaken in controlled temperature environments to decrease the time required to reach equilibrium as well as facilitate dissolution of test compounds. Plasma protein binding values obtained for 10 diverse compounds using standard dialysis equipment and the 96-well dialysis block validates this method. Copyright 2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 92:967-974, 2003

Mesh:

Substances:

Year:  2003        PMID: 12712416     DOI: 10.1002/jps.10332

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  41 in total

1.  Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Authors:  Laura H Jacobson; S Renee Commerford; Sarah P Gerber; Yu Alice Chen; Beatriz Dardik; Frederique Chaperon; Chad Schwartzkopf; Van Nguyen-Tran; Thomas Hollenbeck; Peter McNamara; Xiaohui He; Hong Liu; H Martin Seidel; Anne-Liese Jaton; Jesper Gromada; Sandra Teixeira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

Review 2.  Microdialysis as a tool in local pharmacodynamics.

Authors:  Yanjun Li; Joanna Peris; Li Zhong; Hartmut Derendorf
Journal:  AAPS J       Date:  2006-04-07       Impact factor: 4.009

3.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 4.  Origin and evolution of high throughput screening.

Authors:  D A Pereira; J A Williams
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

5.  Automated solid-phase microextraction and thin-film microextraction for high-throughput analysis of biological fluids and ligand-receptor binding studies.

Authors:  Dajana Vuckovic; Erasmus Cudjoe; Florin Marcel Musteata; Janusz Pawliszyn
Journal:  Nat Protoc       Date:  2010-01-07       Impact factor: 13.491

6.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

7.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Karen M D Holm; Kristian Linnet
Journal:  Int J Legal Med       Date:  2016-04-07       Impact factor: 2.686

8.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

9.  Interpreting physicochemical experimental data sets.

Authors:  Nicola Colclough; Mark C Wenlock
Journal:  J Comput Aided Mol Des       Date:  2015-06-09       Impact factor: 3.686

10.  Determination of drug-like properties of a novel antileishmanial compound: In vitro absorption, distribution, metabolism, and excretion studies.

Authors:  Susanta Kumar Mondal; Nirup B Mondal; Sukdeb Banerjee; Upal Kanti Mazumder
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.